Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft standard CEI-MS-11: Determination of aggregate content… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-091/3
Series
Public comment period
Version
1.0
Published
26 Feb 2026
Last reviewed
26 Feb 2026
Next review
26 Feb 2027
Identifier
10.71829/cei.cp.91
Certainty
Not rated
Cycle
2026 Q1
Window
13 Jan 2026 – 12 Feb 2026
Status
Closed
Submissions
12

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-AGGREGATES-S/012Dr Rosalind Grünbaum-SowandeNothing in the standard addresses transfer of the method between laboratoriesAccepted in part
DRAFT-AGGREGATES-S/006Dr Quintus RautavaaraThe document set should be published in translationNot accepted
DRAFT-AGGREGATES-S/005Dr Gervase CrickhowellA conformance claim is not defined and will be made looselyAccepted
DRAFT-AGGREGATES-S/003Dr Oisín Marchetti-BasseyA single determination is permitted where duplicates would be inexpensiveAccepted in part
DRAFT-AGGREGATES-S/004Dr Rurik Haverkamp-DialloTerms are used in senses that differ from established pharmacopoeial usageAccepted
DRAFT-AGGREGATES-S/002Ignatius ErlingssonQuantitative claims are reproduced without the method that produced themAccepted
DRAFT-AGGREGATES-S/001Dr Rosalind Grünbaum-SowandeA determination does not record the version of the standard it was made underAccepted
DRAFT-AGGREGATES-S/008Dr Wilhelmina ErlingssonReferences should carry a persistent identifier for every cited sourceAccepted in part
DRAFT-AGGREGATES-S/009Dr Ndidi Ravensworth-IlungaPoint estimates are given without an intervalAccepted in part
DRAFT-AGGREGATES-S/010Leonhard AchterbergAcceptance criteria are expressed in terms specific to one instrument familyAccepted in part
DRAFT-AGGREGATES-S/007Dr Adaeze Dunmore-EkpoThe standard does not say what to do with a result outside the expected rangeAccepted
DRAFT-AGGREGATES-S/011Ignatius ErlingssonDeclared interests should appear on the document rather than on a separate pageNoted, no amendment
12 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted5The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part5Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted1The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Nothing in the standard addresses transfer of the method between laboratories — arising from DRAFT-AGGREGATES-S/012. The standard now states the maximum difference between laboratories analysing the same sample at which results are treated as agreeing, and requires that a comparison across laboratories state whether that criterion was met.
  2. A conformance claim is not defined and will be made loosely — arising from DRAFT-AGGREGATES-S/005. Conformance is now defined as meeting every requirement classified as critical together with the stated system suitability criteria, partial conformance must be described by naming the requirements not met, and a claim of conformance made without the sampling…
  3. A single determination is permitted where duplicates would be inexpensive — arising from DRAFT-AGGREGATES-S/003. The standard now requires duplicate preparation and injection with a stated maximum difference between the two, and requires that a difference exceeding it be investigated before any figure is reported.
  4. Terms are used in senses that differ from established pharmacopoeial usage — arising from DRAFT-AGGREGATES-S/004. The three terms now follow established pharmacopoeial usage, the glossary records the definition and its source, and where the Institute uses a term in a narrower sense the departure is stated at first use in the standard.
  5. Quantitative claims are reproduced without the method that produced them — arising from DRAFT-AGGREGATES-S/002. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
  6. A determination does not record the version of the standard it was made under — arising from DRAFT-AGGREGATES-S/001. Every determination reported under this standard now carries the standard identifier and version on its face, and a claim of conformance that does not identify the version is recorded by the Institute as not conformant.
  7. References should carry a persistent identifier for every cited source — arising from DRAFT-AGGREGATES-S/008. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
  8. Point estimates are given without an interval — arising from DRAFT-AGGREGATES-S/009. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
  9. Acceptance criteria are expressed in terms specific to one instrument family — arising from DRAFT-AGGREGATES-S/010. The acceptance criteria are now expressed in instrument-independent quantities, with the conversion from the common manufacturer-specific reporting units given in a note so that a laboratory can check conformance without recalculating by hand.
  10. The standard does not say what to do with a result outside the expected range — arising from DRAFT-AGGREGATES-S/007. The standard now requires that every determination performed on a sample be reported, that a repeat be permitted only where an assignable cause is documented, and that the assignable cause be stated on the face of the report.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.